Research Paper Volume 13, Issue 9 pp 12514—12525
Capsanthin induces G1/S phase arrest, erlotinib-sensitivity and inhibits tumor progression by suppressing EZH2-mediated epigenetically silencing of p21 in triple-negative breast cancer cells
Figure 5. Capsanthin inhibits the growth of MDA-MB-231 cell–derived tumors in mice. (A) The tumor width (W) and length (L) were measured each week with calipers, and the tumor volume was calculated as L × W2 × 0.52. We injected capsanthin <low dose (0.036 mg/kg) and high dose (0.36 mg/kg)> into mice two times a week for 2 weeks, after which they were sacrificed. (B–C) Breast-cancer tumor growth was significantly inhibited in the groups treated with a low dose or high dose of capsanthin (n = 3). *P < 0.05, **P < 0.01. (D) Capsanthin inhibited the cellular level of EZH2 in both the low- and high-dose groups of TNBC tissues as assessed with immunohistochemistry (with anti-EZH2, brown color). (E) Capsanthin decreased the cellular levels of both EZH2 and H3K27me3 in tumor, whereas that of the p21 was increased.